Natalie S. Callander, MD Print Friendly Page
Faculty, University of Wisconsin School of Medicine and Public HealthDr. Callander joined the section of Hematology/Bone Marrow Transplant at the University of Wisconsin in October 2004 as an Associate Professor in the Department of Medicine. Dr. Callander has completed residency at Bellevue Hospital in New York and a Hematology/Oncology fellowship at the University of California-San Diego.
Specialties
UW Health Clinics
UW Carbone Cancer Center
(608) 265-1700
| (800) 323-8942
| Map
Hospital Affiliation(s)
University of Wisconsin Hospital and Clinics (primary)
Languages Spoken
| English |
| Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000. |
UW School of Medicine and Public Health
| Department of Medicine |
Professional Certifications and Education
| Board Certification |
Hematology
Internal Medicine Medical Oncology |
| Fellowship |
University of California, San Diego
|
| Residency |
Bellevue Hospital, New York
|
| Internship |
Bellevue Hospital, NY
|
| Medical School |
Tufts University School of Medicine, Boston, MA, 1985
|
Awards/Honors
Procedures
Our doctors provide a wide range of services. The following list represents some, but not all, of the procedures offered by this physician.
Programs & Conditions
| Research |
Her clinical and research interests include: inpatient and outpatient care of hematology and bone marrow transplant patients and multiple myeloma. |
PubMed Articles
-
Asimakopoulos F Kim J Denu RA Hope C Jensen JL Ollar SJ Hebron E Flanagan C Callander N Hematti P .
Macrophages in multiple myeloma: emerging concepts and therapeutic implications. Leuk Lymphoma. 2013 Apr 11;
[PubMed ID: 23432691]
-
Hebron E Hope C Kim J Jensen JL Flanagan C Bhatia N Maroulakou I Mitsiades C Miyamoto S Callander N Hematti P Asimakopoulos F .
MAP3K8 kinase regulates myeloma growth by cell-autonomous and non-autonomous mechanisms involving myeloma-associated monocytes/macrophages. Br J Haematol. 2013 Mar;160(6):779-84
[PubMed ID: 23252623]
-
Kim J Denu RA Dollar BA Escalante LE Kuether JP Callander NS Asimakopoulos F Hematti P .
Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells. Br J Haematol. 2012 Aug;158(3):336-46
[PubMed ID: 22583117]
-
Young EW Pak C Kahl BS Yang DT Callander NS Miyamoto S Beebe DJ .
Microscale functional cytomics for studying hematologic cancers. Blood. 2012 Mar 8;119(10):e76-85
[PubMed ID: 22262772]
-
Chang JE Peterson C Choi S Eickhoff JC Kim K Yang DT Gilbert LA Rogers ES Werndli JE Huie MS McFarland TA Volk M Blank J Callander NS Longo WL Kahl BS .
VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study. Br J Haematol. 2011 Oct;155(2):190-7
[PubMed ID: 21848883]
-
Markovina S Callander NS O'Connor SL Xu G Shi Y Leith CP Kim K Trivedi P Kim J Hematti P Miyamoto S .
Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-kappaB activity in myeloma cells. Mol Cancer. 2010 Jul 6;9:176
[PubMed ID: 20604947]
-
Markovina S Callander NS O'Connor SL Kim J Werndli JE Raschko M Leith CP Kahl BS Kim K Miyamoto S .
Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells. Mol Cancer Res. 2008 Aug;6(8):1356-64
[PubMed ID: 18708367]
-
Chang JE Juckett MB Callander NS Kahl BS Gangnon RE Mitchell TL Longo WL .
Thalidomide maintenance following high-dose melphalan with autologous stem cell support in myeloma. Clin Lymphoma Myeloma. 2008 Jun;8(3):153-8
[PubMed ID: 18650178]
